Salmeterol

Salmeterol
Clinical data
Trade namesSerevent, Aeromax, Qitai, others
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Respiratory inhalation (Metered-dose inhaler (MDI), Dry-powder inhaler (DPI))
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding96%
MetabolismLiver (CYP3A4)
Elimination half-life5.5 hours
Identifiers
  • (RS)-2-(hydroxymethyl)-4-{1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl}phenol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.122.879 Edit this at Wikidata
Chemical and physical data
FormulaC25H37NO4
Molar mass415.574 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • OCc1cc(ccc1O)[C@H](O)CNCCCCCCOCCCCc2ccccc2
  • InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2/t25-/m1/s1 checkY
  • Key:GIIZNNXWQWCKIB-RUZDIDTESA-N checkY
 ☒NcheckY (what is this?)  (verify)

Salmeterol is a long-acting β2 adrenergic receptor agonist (LABA) used in the maintenance and prevention of asthma symptoms and maintenance of chronic obstructive pulmonary disease (COPD) symptoms.[2] Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).[3]

It was patented in 1983 and came into medical use in 1990.[4] It is marketed as Serevent in the US.[5] It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002.[2][6] It is available as an MDI in other countries as of 2020.[7]

  1. ^ Cite error: The named reference Serevent FDA label was invoked but never defined (see the help page).
  2. ^ a b "global initiative for chronic obstructive disease" (PDF). goldcopd.org. Archived from the original (PDF) on 24 September 2015. Retrieved 30 October 2014.
  3. ^ "National Asthma Education and Prevention Program". Retrieved 30 October 2014.
  4. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 543. ISBN 9783527607495.
  5. ^ "Salmeterol inhalation index". Retrieved 30 October 2014.
  6. ^ "Benefit Risk Assessment of Salmeterol for the Treatment of Asthma in Adults and Children" (PDF). fda.gov. Archived from the original (PDF) on 26 January 2018.
  7. ^ "Serevent Dosieraeros 25 mcg FCKW-frei". compendium.ch (in German). Archived from the original on 2021-07-24. Retrieved 2020-03-25.